about
Hipos-Er (Hypoglycemia in Portugal Observational Study - Emergency Room): Costs And Health Care Resource Consumption Data.Severe Hypoglycemia Among Patients With Type 2 Diabetes Requiring Emergency Hospital Admission: The HIPOS-ER Study.Patient's access to healthcare and treatment in rheumatoid arthritis: the views of stakeholders in Portugal.Interventions aiming to reduce early retirement due to rheumatic diseases.Real-life effectiveness of Golimumab in biologic-naïve patients with rheumatoid arthritis - data from the Rheumatic Diseases Portuguese Register (Reuma.pt).Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt- a national health survey.Inadequate pain relief among patients with primary knee osteoarthritis.Inadequate pain relief among patients with primary knee osteoarthritis.Inadequate Pain Relief Among Patients With Primary Knee Osteoarthritis - Analysis From The Portuguese Sample Of The Survey Of Osteoarthritis Real World Therapies (Sort).Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.The economic impact of early retirement attributed to rheumatic diseases: results from a nationwide population-based epidemiologic study.The cost of managing severe hypoglycemic episodes in Type 2 diabetic patients.Impact of hypoglycemic events and HbA1c level on sulfonylurea discontinuation and down-titration.EpiReumaPt: how to perform a national population based study - a practical guide.Risk factors associated with treatment discontinuation and down-titration in type 2 diabetes patients treated with sulfonylureas.Indirect costs associated with early exit from work attributable to rheumatic diseases.[Epidemiology of hip fractures and its social and economic impact. An update for 2014].CoReumaPt protocol: the Portuguese cohort of rheumatic diseases.Association of rheumatic diseases with early exit from paid employment in Portugal.Perturbation of membrane dynamics in nerve cells as an early event during bilirubin-induced apoptosis.Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.Patients' access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries.EpiReumaPt- the study of rheumatic and musculoskeletal diseases in Portugal: a detailed view of the methodology.Implant Versus Oral Contraception Use: 3-Years Budget Impact Analysis for the National Heal System in Portugal.Effectiveness of A Referral Program for Early Arthritis Diagnosis At Primary Care Centers in Portugal - Preliminary Results from the Siara Study.Self-Reported Rheumatic Diseases and Early Retirement in Portugal.Years of Working Life Lost Caused By Osteoarthritis In Portugal.Years of Working Life Lost Caused By Rheumatic Diseases In Portugal.Cost of Early Retirement Caused By Rheumatic Diseases In Portugal.Characterization of Osteoporosis In Portugal - Treatment Patterns And Reasons for Under-Treatment and Non-Persistence With Pharmacological Treatments.The NHS Expenditure Managing Severe Hypoglycemia Episodes in Type 2 Diabetic Patients in Portugal.Regispt: Registry of Registries In Portugal.The Impact Of Pharmaceutical Innovation On Longevity In Portugal, 2002-2010.Direct Costs And Healthcare Resource Use Associated With Advanced Melanoma In Portugal.The Impact Of Pharmaceutical Innovation On Premature Cancer Mortality In Portugal.A Comparison of the Impact of Rheumatic Diseases and Other Chronic Diseases on Early Retirement in Portugal.Early Retirement Indirect Costs Attributable to Rheumatic Diseases in Portugal.Cost and Burden Of Hypercholesterolemia In Portugal.Hipos-ER (Hypoglycemia in Portugal Observational Study - Emergency Room): Clinical Outcomes in Admitted Patients.Hipos-ER (Hypoglycemia in Portugal Observational Study - Emergency Room): Clinical Outcomes in the Emergency Room.
P50
Q31097682-54CFA864-6ABD-4679-92A2-88B89EB09D41Q33168702-2A74D82F-EF1F-4A6B-9040-2D740370640BQ34997800-BCDB636A-358D-45AE-ADBA-8ABC329364B5Q36332884-EBC75F80-ED04-4F89-9791-BC98A2E199F7Q36332887-A6DC9433-A808-4337-BA2F-55CF42CFC6A1Q36517265-E9B58975-37FF-4109-9A9C-76958C53272BQ38768516-1AC6497D-1244-4ED1-A68A-812013202246Q39152231-89597979-71F7-499F-8F0F-D94BA1579E9EQ39199234-725E69E7-1833-40DE-AD2F-3CE17C193EC9Q39478177-C6EDFC30-FCE2-4591-9B3A-6C59B231AD60Q39487702-05809E28-6673-42CD-B4B6-6B3E03EF9ACAQ40024706-40415FEA-8BB3-48D1-B57D-E391F6D944ABQ40681506-7778CA28-0371-495E-87C6-E14981EBE8EEQ40685081-1A50E1AE-9A26-4FA6-9C52-4D20B3F0BD06Q40756010-5E883543-44F3-419E-B30F-DAD39D25367EQ41507083-0DC1B665-93A0-4152-809F-14115946195CQ41732084-4614AFEF-2FB5-45E0-91F6-C39E4CD5E193Q42658213-9F1B133F-D89B-4A01-A297-D9DBC2D9A231Q44931445-98236DCA-EA2B-4DC4-B058-4C0E33668ABCQ48594641-943C1A5C-EE66-42B3-BCDD-3E03A8417082Q49136984-B64DABF1-D89D-4FA8-B756-A249DB8F2D9AQ50122706-8F69C948-737C-426F-9E97-67116DCB78E0Q50576899-4F45034A-5E45-40B8-A33F-3E3901B6AF6BQ52800327-40925DB7-714E-49BB-B696-7332C79BC73AQ52800343-1830AD25-1C01-4088-AA4A-375F6AA2E730Q52800347-F71B9CE7-8FF5-4910-8FF5-D63E7ECACE39Q52800352-B1D001E7-79ED-4C1D-B4F5-1A1FD15D40C0Q52800355-6E7C192E-E918-466A-80E6-63613F4D9314Q52800359-5CF16C62-C76B-40A0-9679-3E88E12C9DA3Q52800362-B86228E0-8032-48D3-B92F-B9AF12CE14A3Q52800365-B51FC648-72F5-4EF7-A709-A4E8D32780EFQ52800383-21A1CEB3-E349-4F06-A2F1-4E613820C305Q52800388-ECA3EA96-8035-420C-B156-4E7C5254FD56Q52800402-7ACCE181-7F1D-4971-8EE3-4D2F7458A57DQ52800405-EC69561C-ABA7-4CBE-AB16-0AE1631EE354Q52801023-2B6EDA6A-61FB-4638-9A47-C65417A13BB7Q52801030-527600F4-878F-4147-9136-EBC432FD5A6DQ52801043-9ACB059D-1B9F-4F1F-B14D-4906242C0515Q52801046-B100AE5E-9C12-4C08-BCE8-5B16A27694D7Q52801049-9DCEE436-A507-4B7A-8293-3DB2F58E2C32
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Pedro A Laires
@ast
Pedro A Laires
@en
Pedro A Laires
@es
Pedro A Laires
@nl
Pedro A Laires
@sl
type
label
Pedro A Laires
@ast
Pedro A Laires
@en
Pedro A Laires
@es
Pedro A Laires
@nl
Pedro A Laires
@sl
altLabel
Laires P
@en
Laires PA
@en
prefLabel
Pedro A Laires
@ast
Pedro A Laires
@en
Pedro A Laires
@es
Pedro A Laires
@nl
Pedro A Laires
@sl
P106
P21
P214
47150030759510961013
P31
P496
0000-0002-1930-7913